Best of the Week
Most Popular
1. Climate Change Mass Extinction - Birds, Bees and Bugs: Going Going Gone - Richard_Mills
2.A Purrrfect Gold Price Setup! - Peter_Degraaf
3.Who Finances America's Borrowing? Recession Indicator for Independent Thinkers Part 2 - F_F_Wiley
4.America’s One-sided Domestic Financial War - Raymond_Matison
5.Gold Price Summer Doldrums - Zeal_LLC
6.Two Key Events Will Unleash Gold - Jim_Willie_CB
7.Billionaire Schools Teacher in NAFTA Trade Talks - Richard_Mills
8.Get Out Of Crypto Cannabis Bubble Before It Pops and Move Into Bargain Basement Miners - Jeb_Handwerger
9.Stock Market Could Pullback for 1-2 weeks, But Medium Term Bullish - Troy_Bombardia
10.G7 Chaos, Central Banks and US Fed Will Drive Stock Prices This Week - Chris_Vermeulen
Last 7 days
Soybean Price Hits 9 Year Low Due to Trade War - 24th Jun 18
Small Cap Stocks, Technology and Pharma To Drive A Renewed Market Rally - 24th Jun 18
Gerald Celente: Why You Still Need Guns, Gold, and a Getaway Plan... - 23rd Jun 18
Cheap Gold Stocks Bottom Basing - 23rd Jun 18
A Trade War Won’t Be Good for the US Dollar - 23rd Jun 18
SPX/Gold, Long-term Yields & Yield Curve 3 Amigos Update - 22nd Jun 18
Gold - How Long Can This Last? - 22nd Jun 18
Dow Has Fallen 8 days in a Row. Medium-long Term Bullish for Stocks - 22nd Jun 18
Trouble Spotting Market Trends? This Can Help - 22nd Jun 18
Financial Markets Analysis and Trend Forecasts 2018 - A Message from Nadeem Walayat - 21st Jun 18
SPX Bouncing Above Support - 21st Jun 18
Things You Need To Know If You Want To Invest In Bitcoin Now - 21st Jun 18
The NASDAQ’s Outperformance vs. the Dow is Very Bullish - 21st Jun 18
Warning All Investors: Global Stock Market Are Shifting Away From US Price Correlation - 20th Jun 18
Gold GLD ETF Update… Breakdown ? - 20th Jun 18
Short-term Turnaround in Bitcoin Might Not Be What You Think - 19th Jun 18
Stock Market’s Short Term Downside Will be Limited - 19th Jun 18
Natural Gas Setup for 32% Move in UGAZ Fund - 19th Jun 18
Magnus Collective To Empower Automation And Artificial Intelligence - 19th Jun 18
Trump A Bull in a China Shop - 19th Jun 18
Minor Car Accident! What Happens After You Report Your Accident to Your Insurer - 19th Jun 18
US Majors Flush Out A Major Pivot Low and What’s Next - 18th Jun 18
Cocoa Commodities Trading Analysis - 18th Jun 18
Stock Market Consolidating in an Uptrend - 18th Jun 18
Russell Has Gone Up 7 Weeks in a Row. EXTREMELY Bullish for Stocks - 18th Jun 18
What Happens Next to Stocks when Tech Massively Outperforms Utilities and Consumer Staples - 18th Jun 18
The Trillion Dollar Market You’ve Never Heard Of - 18th Jun 18
The Corruption of Capitalism - 17th Jun 18
North Korea, Trade Wars, Precious Metals and Bitcoin - 17th Jun 18
Climate Change and Fish Stocks – Burning Oxygen! - 17th Jun 18
A $1,180 Ticket to NEW Trading Opportunities, FREE! - 16th Jun 18
Gold Bullish on Fed Interest Rate Hike - 16th Jun 18
Respite for Bitcoin Traders Might Be Deceptive - 16th Jun 18

Market Oracle FREE Newsletter

5 "Tells" that the Stock Markets Are About to Reverse

The Smart Money Is Piling Into Regenerative Medicine

Companies / BioTech Apr 18, 2017 - 06:12 PM GMT

By: John_Mauldin

Companies

BY PATRICK COX : The Congressional Budget Office released its long-term budget outlook. This report should have sparked a national discussion about societal aging, but big media largely ignored it.

Fortunately, there are signs that smart investors are hedging this failure by investing in regenerative medicine (RM).


Over the last few years, the CBO has emerged as one of the few grownups in the room. Its annual budget projections have focused on population aging as the main driver of US federal deficit and the debt.

The core message of "The 2017 Long-Term Budget Outlook" is simple: Mandated transfer payments for our increasingly older demographic are just too much.

These costs have crippled the federal government and the private sector. The CBO warns that this is causing economic instability. As a result, a cascade of financial crises is more and more likely.

Only three parts of the budget are growing in relation to the whole. They are Social Security, health care, and net interest.

Social Security is clearly about the aged, so are increased healthcare costs. The CBO says those costs will continue to rise.

The reason? We are living longer and new treatments for age-related diseases continue to emerge. But even if dramatic cuts are made to benefits for the aged, it will only slow the meltdown.

Why? Long-term demographic trends will continue. Life expectancies will keep rising as birthrates fall.

Progressive Approval Could Be a Game Changer for RM

Japan is ahead of the curve in terms of demographics, but the US will soon get there. It is important to note that Japan has failed to produce political solutions to its budgetary woes.

But Japan has started to look at this problem through a different lens. These economic issues can be solved by addressing aging itself.

Japanese lawmakers have instituted progressive approval for regenerative medicine (RM). That means after successful safety trials, RM therapies can be approved. Data will then be collected and made public.

Critics of progressive approval claim it could legalize ineffective treatments. The Japanese think that the risk of delaying true anti-aging therapies is greater than the risk of approving ineffective treatments.

Japanese leadership seems to have had a major impact on the investment community. Now, US firms are eyeing the prospect of gaining much faster approvals in Japan.

This has major financial implications for RM biotechs.

Investing in Regenerative Medicine

A recent report from Goldman Sachs includes a section titled “The Coming Age of Regenerative Medicine.”

Business Insider article about the report is aptly titled “Money is pouring in to a hot new area of science that could change the way we think about aging.

According to the article, “venture capital in companies pursuing regenerative medicine increased from $296 million in 2011 to $807 million in 2016, growing roughly 34% year-over-year.”

The author also writes that, “by the report's count, 80 regenerative-medicine companies received funding in the last three years, and the deals related to regenerative medicine accounted for almost half of the top venture-capital deals in 2015 and 2016.”

Two years ago, Fed Chair Janet Yellen threw cold water on biotech. She compared it to overheated social media.

I think Yellen was wrong. And her off-the-cuff comment hurt startups struggling to find funds in order to survive.

On the other hand, economist John Mauldin has long predicted that there will be a bubble following the public’s realization of the power of emerging RM.

But bubbles aren’t uniform things. History teaches us that under- and overvalued companies exist at almost all times.

Some of the companies covered in the Goldman report seem overvalued to me. Analysts, though, are frequently wrong.

We never know what a company is truly worth until its products are judged by consumers.

The Goldman report discusses Samumed, a private RM company. With $300 million in funding, it’s valued at a staggering $12 billion. Samumed’s drug platform aims to regenerate various tissues such as bone, cartilage, hair, and skin.

As Samumed is not yet public, my interest in the company is academic. The larger question is what it means to more established RM companies.

AgeX Plans to Reverse Aging

The original RM company, Geron, is now folded into BioTime subsidiary Asterias. BioTime (*see disclosure below) is the core of my RM portfolio. This is largely because of Michael West, who pioneered the SCI therapy at Geron over 20 years ago.

To date, West's stem cell treatment for spinal cord injury is the most successful example of RM, but it’s 20 years old. Since that time, West’s research has progressed much further.

Last week, BioTime announced a new subsidiary, AgeX. AgeX has a range of stem cell IPs aimed at conditions such as cardiovascular repair and diabetes.

The true goals of AgeX, though, are much more radical. West intends to reverse aging … hence the company name.

He believes he can reactivate embryonic gene pathways to completely regenerate limbs and organs, including eyes, joints, and hearts. AgeX’s induced tissue regeneration technology would not only regenerate damaged and missing tissues.

It would turn back the biological clock of aging. West gave an excellent talk on this new science in his keynote address at the 2016 World Stem Cell Summit.

If he’s right, we’ll still have lots of problems, but the cost of age-related diseases won’t be one of them.

Stay in the Loop on Life-Extending Research with Patrick Cox's Tech Digest

This weekly newsletter by biotech expert Patrick Cox highlights research that is much more advanced than most people know, and the profit potential for investors is vast. Read about the latest breakthroughs—from new, non-invasive cancer treatments to age-reversing nutraceuticals and vaccines that kill any virus–as well as the innovative companies that work on them. Get Tech Digest free in your inbox every Monday.

(*Disclosure: The editors or principals of Mauldin Economics have a position in this security. They have no plans to sell their position at this time. There is an ethics policy in place that specifies subscribers must receive advance notice should the editors or principals intend to sell.)

John Mauldin Archive

© 2005-2018 http://www.MarketOracle.co.uk - The Market Oracle is a FREE Daily Financial Markets Analysis & Forecasting online publication.


Post Comment

Only logged in users are allowed to post comments. Register/ Log in

6 Critical Money Making Rules